Hunan Jingfeng Pharmaceutical Co.,Ltd. (SHE:000908)
China · Delayed Price · Currency is CNY 7.02
-0.01 (-0.14%)
Feb 3, 2026, 3:04 PM CST
SHE:000908 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 388.42 | 411.27 | 645.32 | 822.56 | 771.86 | 866.83 |
Other Revenue | 4.76 | 4.76 | 11.58 | 18.1 | 39.33 | 11.09 |
| 393.19 | 416.03 | 656.89 | 840.66 | 811.18 | 877.92 | |
Revenue Growth (YoY) | -1.15% | -36.67% | -21.86% | 3.63% | -7.60% | -34.68% |
Cost of Revenue | 133.11 | 155.08 | 197.92 | 205.82 | 323.64 | 330.55 |
Gross Profit | 260.08 | 260.95 | 458.97 | 634.83 | 487.55 | 547.37 |
Selling, General & Admin | 246.26 | 249.61 | 502.89 | 591.81 | 711.34 | 832.57 |
Research & Development | 12.19 | 13.02 | 52.51 | 35.64 | 38.63 | 252.88 |
Other Operating Expenses | 18.25 | 9.72 | 10.77 | 11.98 | 27.36 | 16.37 |
Operating Expenses | 278.19 | 266.27 | 563.35 | 654.27 | 797.37 | 1,246 |
Operating Income | -18.11 | -5.31 | -104.38 | -19.44 | -309.83 | -698.83 |
Interest Expense | -28.98 | -40.34 | -41.89 | -52.23 | -85.85 | -105.92 |
Interest & Investment Income | 265.89 | 264.4 | 5.3 | 1.12 | 249.89 | 224.55 |
Currency Exchange Gain (Loss) | 0.03 | 0.03 | 0.04 | 0.15 | -0.05 | 0.65 |
Other Non Operating Income (Expenses) | 18.24 | 0.81 | 0.51 | 1.85 | -19.08 | -7.78 |
EBT Excluding Unusual Items | 237.08 | 219.6 | -140.42 | -68.54 | -164.92 | -587.32 |
Impairment of Goodwill | - | - | - | - | - | -360.83 |
Gain (Loss) on Sale of Investments | -0.82 | -1.25 | 24.81 | 13.82 | -3.79 | -180.93 |
Gain (Loss) on Sale of Assets | -3.71 | -3.36 | 7.56 | 9.8 | 55.89 | -0.18 |
Asset Writedown | -17.49 | -19.03 | -83.76 | -39.56 | -42.79 | -19.24 |
Legal Settlements | -20.8 | -20.8 | -6.12 | -15.33 | -13.72 | - |
Other Unusual Items | -21.58 | -10.62 | 3.31 | 14.17 | 13.89 | -3.41 |
Pretax Income | 172.67 | 164.53 | -194.62 | -85.63 | -155.44 | -1,152 |
Income Tax Expense | 6.96 | 5.08 | 32.84 | 9.62 | 46.2 | 3.39 |
Earnings From Continuing Operations | 165.71 | 159.45 | -227.46 | -95.25 | -201.64 | -1,155 |
Minority Interest in Earnings | -9.15 | -7.14 | -8.64 | -27.31 | 37.98 | 86.79 |
Net Income | 156.56 | 152.3 | -236.1 | -122.56 | -163.66 | -1,069 |
Net Income to Common | 156.56 | 152.3 | -236.1 | -122.56 | -163.66 | -1,069 |
Shares Outstanding (Basic) | 879 | 880 | 880 | 880 | 880 | 883 |
Shares Outstanding (Diluted) | 879 | 880 | 880 | 880 | 880 | 883 |
Shares Change (YoY) | 0.01% | 0.02% | -0.02% | -0.01% | -0.36% | 0.03% |
EPS (Basic) | 0.18 | 0.17 | -0.27 | -0.14 | -0.19 | -1.21 |
EPS (Diluted) | 0.18 | 0.17 | -0.27 | -0.14 | -0.19 | -1.21 |
Free Cash Flow | 0.3 | -6.93 | 24.64 | 109.75 | 85.72 | -367.72 |
Free Cash Flow Per Share | - | -0.01 | 0.03 | 0.13 | 0.10 | -0.42 |
Gross Margin | 66.15% | 62.72% | 69.87% | 75.52% | 60.10% | 62.35% |
Operating Margin | -4.61% | -1.28% | -15.89% | -2.31% | -38.19% | -79.60% |
Profit Margin | 39.82% | 36.61% | -35.94% | -14.58% | -20.18% | -121.71% |
Free Cash Flow Margin | 0.08% | -1.67% | 3.75% | 13.05% | 10.57% | -41.89% |
EBITDA | -1.89 | 20.66 | -65.39 | 32.24 | -212.35 | -617.37 |
EBITDA Margin | -0.48% | 4.97% | -9.95% | 3.83% | -26.18% | -70.32% |
D&A For EBITDA | 16.22 | 25.98 | 38.99 | 51.68 | 97.47 | 81.45 |
EBIT | -18.11 | -5.31 | -104.38 | -19.44 | -309.83 | -698.83 |
EBIT Margin | -4.61% | -1.28% | -15.89% | -2.31% | -38.19% | -79.60% |
Effective Tax Rate | 4.03% | 3.09% | - | - | - | - |
Revenue as Reported | 393.19 | 416.03 | 656.89 | 840.66 | 811.18 | 877.92 |
Advertising Expenses | - | 3.92 | 20.6 | 49.36 | 73.33 | 39.49 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.